Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia

JAMA Dermatology

Volumn 149, Issue 5, 2013, Pages 637-639

  Samimi, Sara ^a   Chu, Emily ^a   Seykora, John ^a   Loren, Alison ^a   Vittorio, Carmela ^a   Rook, Alain ^a   Rosenbach, Misha ^a   Kim, Ellen J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEPIGMENTATION; DISEASE DURATION; DRUG EFFECT; DRUG SAFETY; EYEBROW; EYELASH; FEMALE; GRAFT VERSUS HOST REACTION; HAIR DISCOLORATION; HAIR ROOT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA RELAPSE; LEUKOTRICHIA; NATURAL KILLER CELL; PNEUMONIA; PRIORITY JOURNAL; SCALP HAIR; SKIN BIOPSY; TREATMENT OUTCOME;

ADULT; DRUG ERUPTIONS; FEMALE; HAIR DISEASES; HAIR FOLLICLE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 84877862816     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.75     Document Type: Article

References (5)

1. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors: a review on pharmacology, metabolism, and side effects. Curr Drug Metab. 2009;10(5):470-481.
2. Pavlů J, Marin D. Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials. Clin Lymphoma Myeloma. 2009;9(6):417-424.
3. Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13(3):205-220. (Pubitemid 41209013)
4. 'Tomita Y, Akiyama M, Shimizu H. PDGF isoforms induce and maintain anagen phase of murine hair follicles. J Dermatol Sci. 2006;43(2):105-115.
5. Sun A, Akin RS, Cobos E, Smith J. Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor. J Drugs Dermatol. 2009;8(4):395-398.